BTIG Reiterates Buy Rating on Ceribell (CBLL)

BTIG analyst Marie Thibault reiterated a Buy rating and $30.00 price target on Ceribell (NASDAQ: CBLL).

The analyst commented: "Next week, we will be hosting investor meetings with Ceribell CEO Jane Chao, PhD and CFO Scott Blumberg in New York City. CBLL is the first entrant and market leader in point-of-care (POC) rapid EEG, leveraging its proprietary AI-driven Clarity algorithm, the first to receive an on-label indication for Electrographic Status Epilepticus (ESE) diagnosis. Earlier this year, the company received FDA approval for the Ceribell Delirium Monitor and positive pilot feedback has supported a pull forward of the full commercial launch to 4Q26. We recently published a physician survey of 24 U.S. Ceribell users (see here), which pointed to a ~30% CAGR in headband volumes between 2025-2028. 79% of our respondents are planning to adopt the Ceribell Delirium Monitor, implying a +19% incremental increase in headband use on top of expected 2027 ESE volumes. We see these survey results as validating robust physician interest in CBLL's expanding platform. We believe the company is on track for a long runway of growth ahead, underpinned by the delirium launch, pediatric/neonate ramp, and a full algorithm and hardware pipeline. Below, a quick refresher on the CBLL story and what we'll be asking the team."

For an analyst ratings summary and ratings history on Ceribell click here. For more ratings news on Ceribell click here.

Shares of Ceribell closed at $23.43 yesterday.

You May Also Be Interested In

• Raymond James Starts Rocket Lab USA (RKLB) at Outperform
• ONEOK Inc (OKE) PT Raised to $93 at TD Cowen
• Tempus AI Inc (TEM) PT Raised to $66 at H.C. Wainwright